Tema Etfs LLC Sells 60,131 Shares of Immunome, Inc. $IMNM

Tema Etfs LLC lessened its holdings in Immunome, Inc. (NASDAQ:IMNM) by 37.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 102,055 shares of the company’s stock after selling 60,131 shares during the quarter. Tema Etfs LLC’s holdings in Immunome were worth $2,192,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of IMNM. Assetmark Inc. acquired a new position in shares of Immunome during the 3rd quarter worth $39,000. BIT Capital GmbH acquired a new stake in Immunome in the third quarter valued at about $69,000. BNP Paribas Financial Markets boosted its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Immunome in the third quarter valued at about $76,000. Finally, Tower Research Capital LLC TRC grew its position in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Insider Activity

In other news, Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $20.47, for a total transaction of $753,296.00. Following the completion of the sale, the director owned 369,347 shares of the company’s stock, valued at $7,560,533.09. This trade represents a 9.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 7.69% of the company’s stock.

Immunome Trading Down 2.7%

Shares of IMNM opened at $21.84 on Friday. The firm’s fifty day simple moving average is $22.42 and its two-hundred day simple moving average is $19.13. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $27.65. The stock has a market capitalization of $2.47 billion, a P/E ratio of -9.02 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). As a group, research analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IMNM has been the subject of a number of research reports. HC Wainwright began coverage on shares of Immunome in a report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Stephens lowered their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, March 4th. Leerink Partners set a $40.00 price objective on shares of Immunome in a research note on Monday, December 15th. Finally, Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.